Abhilasha Patel, MD
Radiation Oncology · Houston, TXNPI 1649405382
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Bayer accounts for 95.8% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $37,955 and has fallen 97.4% since, to $979 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $338.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$73K
- Tactile Systems Technology Inc$371
- Myriad Genetic Laboratories, Inc.$354
- Johnson & Johnson$327
- Novartis$293
- Merck$176
- plus $2K from 35 others
What the payments were for
- Consulting fees$19,12825%
- Speaking & faculty fees$44,38159%
- Travel & lodging$7,56110%
- Food & beverage$4,7886%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,858 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 13 | $374 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $259 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Houston
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Joe ChangHouston$50K
- Daniel GomezHouston$47K
- David RosenthalHouston$40K
- Andrew FarachHouston$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.